Cancer charity to help Hummingbird's antibody to take flight

8 August 2019

The world’s leading cancer charity has teamed up with Singapore-based Hummingbird Bioscience to develop the company’s anti-HER3 antibody drug, HMBD-001.

This candidate, a potential treatment for people with HER3-driven cancer, was brought to the Cancer Research UK program through its Clinical Development Partnerships scheme, having been discovered by Hummingbird.

Under the terms of the newly-announced partnership, Cancer Research UK’s Centre for Drug Development will fund the program, manufacture the clinical grade antibody and conduct a Phase I clinical trial to evaluate drug safety, toxicity and efficacy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK